The University of Toledo

Biochemistry & Cancer Biology : Manohar Ratnam, Ph.D.

Skip to menu | Skip to content | Skip to search | Skip to global navigation
  • Home
  • About UT
  • Directions/Maps
  • Campus Directory
  • Contact
  • myUT
  • Advanced Search
  • Feedback
  • Prospective Students
  • Admission
  • Academics
  • Campus Life
  • Current Students
  • Faculty & Staff
  • Research
  • Athletics
  • Alumni & Community
  • Print
Biochemistry & Cancer Biology
  • No top menu
  • <!-- no script -->
    Welcome 
    • Overview
    • Faculty Profiles and Interests
    • Support Personnel
    • Laboratory Facilities
    • NEWS & Announcements
    • 2009-2010 Seminar Series
    • Graduate Programs
    • Current Students
    • Student-Faculty Publications 
    • Recruitment  
    Related Links
    • Cancer Biology Track 
    • Cancer Center
    • Electron Microscopy Facility
    • Flow Cytometry Core Lab
    • Genomics Core Lab
    • Proteomics Core Lab
    • Advanced Microscopy & Imaging Center 
    Generic
    no links

    Manohar Ratnam, Ph.D.
    Manohar Ratnam, Ph.D.
    Professor of Biochemistry & Cancer Biology
    manohar.ratnam@utoledo.edu 

    RESEARCH INTERESTS:

    For several years, my laboratory pioneered the discovery and characterization of the folate receptor gene family and helped to establish the potential utility of FR isoforms in the targeted therapy of various types of cancer as well as inflammatory diseases. Those studies involved detailed studies of structure-function and gene regulation of FRs. More recently, we have discovered non-classical mechanisms of transcriptional regulation of FR genes by the nuclear receptor superfamily, including various steroid receptors and the retinoic acid receptor. The new findings have broad implications in global gene regulation mechanisms and in the mechanism-based treatment of different cancers including breast cancer, ovarian cancer, prostate cancer and myelogenous leukemias. In the foreseeable future, my laboratory’s broad research interests will expand into the molecular endocrinology of nuclear receptors, particularly in relation to new mechanisms of gene regulation, while continuing to also pursue advanced studies of FR-targeted therapeutics. The specific disease focus of my current research includes: (i) Early detection of breast and ovarian cancer (ii) Mechanism-based improvements over tamoxifen for long-term administration as a breast cancer chemopreventative/therapeutic agent in pre-menopausal women (iii) New mechanism based approaches to treating proliferative disorders of the prostate (iv) Molecular approaches to targeted drug delivery in acute myelogenous leukemia.

    Member of the mentoring faculty for the Biomedical Sciences Graduate Program (Cancer Biology track and Cardiovacular and Metabolic Diseases track).

    EDUCATION:

    Ph.D. 1983 Indian Institute of Science, Bangalore, India (Biochemistry)
    M.Sc. 1978 University of Mysore, Mysore, India (Biosciences) First Rank (First in University)
    B.Sc. 1976 University of Mysore, Mysore, India (Chemistry, Botany and Zoology)

    ACADEMIC APPOINTMENTS:

    2005 - present Scientific Director, University Cancer Center
    2005 - present Harold and Helen McMaster Chair in Biochemistry and Molecular Biology
    1998 - present: Professor, Biochemistry and Cancer Biology, University of Toledo College of Medicine 
    1994 - 1998: Associate Professor, Biochemistry and Molecular Biology Medical University of Ohio
    1993 - 1997: Consultant Eli Lilly and Co., Indianapolis, IN.
    1990 - 1993: Assistant Professor, Biochemistry and Molecular Biology Medical University of Ohio
    1990 Affiliate Assistant Professor, Dept. of Pathobiology, University of Washington, Seattle, WA.
    1989 - 1990 Senior Scientist Oncogene, Bristol-Myers Squibb Co.
    1986 - 1989 Instructor, Medical University of Ohio
    1985 - 1986 Research Associate, Biochemistry Medical College of Ohio
    1983 - 1985 Postdoctoral Fellow, Receptor Biology Laboratory Salk Institute, San Diego, CA
    1980 - 1983 Editorial Assistant Journal of Bioscience

    PROFESSIONAL AFFILIATIONS & ACTIVITIES:

    Regular Member of NIH Study Section, Basic Mechanisms of Cancer Therapeutics (BMCT) - March 2007-February 2011
    Regular Member of NIH Study Section, Experimental Therapeutics - July 1997-June 2001
    Ad hoc Reviewer for NIH Study Section BMCT - November 2005, June 2006, October 2006, January 2007
    Ad hoc Reviewer for NIH Study Section ET-1 - February 1996, October 1996, February 1997, June 2003
    NIH Special Emphasis Panels - May 1999, April 2000, August 2000, December 2000 (Chair), December 2003, June 2004, December 2004, August 2005
    External Reviewer for Ohio University College of Osteopathic Medicine's competitive grant program - November 2006
    External Grant Reviewer for Ohio Cancer Research Associates - April 2001
    Member of Review Committee for American Cancer Society (Ohio Chapter) - 1995-1998
    Grant Reviewer for Veterans Administration Office of External Reviews - September 2001
    External Grant Reviewer for The Hospital for Sick Children Foundation, Toronto, Ontario, Canada - 1998-present
    Grant Reviewer for American Chemical Society Petroleum Research Fund - 2001
    Grant Reviewer for Biotechnology and Biological Sciences Research Council, U.K. - 2002

    REVIEWER FOR THE FOLLOWING JOURNALS:

    Nature Medicine, Molecular Biology of the Cell, Journal of Clinical Investigation, Blood, Cancer Research, Clinical Cancer Research, The Journal of Biological Chemistry, Journal of Molecular Biology, Biochemistry, Nucleic Acids Research, American Journal of Physiology, Biochemical Pharmacology, Gynecologic Oncology, Cell Proliferation, Biochimica et Biophysica Acta, Journal of Nutrition, Archives of Biochemistry and Biophysics, Gene, Developmental Dynamics, International Journal of Cancer, Biotechnology & Applied Biochemistry

    REPRESENTATIVE PUBLICATIONS:

    Zhang, J., Gonit, M., Salazar, MD, Shatnawi, A., Shemshedini, L., Trumbly, R., and Ratnam, M. (2009) C/EBPalpha redirects androgen receptor signaling through a unique bimodal interation.  Oncogene  [Epub ahead of print] PMID: 19901962

    Elnakat, H., Gonit, M., d'Alincourt Salazar, M., Zhang, J., Basrur V., Gunning, W., Kamen, B., and Ratnam, M. (2009) Regulation of folate receptor internalization by protein kinase C alpha.  Biochemistry 48:8249-8260.

    van der Heijden, J.W., Oerlemans, R., Dijkmans, B.A.C., Qi, H., van der Laken, C.J., Lems, W.F., Jackman, A.L., Kraan, M.C., Tak, P.P., Ratnam, M., and Jansen G. (2009) Folate receptor-B as a potential delivery route for novel folate antagonists to macrophages in synovial tissue of rheumatoid arthritis patients.  Arthritis and Rheumatism 60:12-21.

    Zhang, J., Wilkinson, J.E., Gonit, M., Keck, R., Selman. S. and Ratnam, M. (2008) Expression and sub-cellular localization of the CCAAT/enhancer binding protein α in relation to postnatal development and malignancy of the prostate. Prostate 68:12-1214.

    Blaser, B., Gonit, M., Qi, H., Shatnawi, A., Guimond, M., Lee, R.J., and Ratnam, M. (2007) Induction of folate receptor type ß in a bone marrow engraftment model of acute myelogenous leukemia.  Leukemia 21: 2233-2235.

    Hao, H., d'Alincourt-Salazar, M., Kelley, K.M.M., Shatnawi, A., Mukherjee, S., Shah, Y.M. and Ratnam, M. (2007) Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by Tamoxifen.  Oncogene 13:7872-7884.

    Lu, Y., Wu., J., Wu, J., Gonit, M., Yang, X., Lee, A., Xiang, G., Li, H., Liu, S., Marcucci, G., Ratnam, M.*, and Lee, R.* (2007) Formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.  Mol. Pharm. 4:707-712.  (*equal contributors)

    Shatnawi, A., Tran, T. and Ratnam, M. (2007) R5020 and RU486 Act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism.  Mol. Endocrinol. 21:635-650.

    Salazar, M.D., and Ratnam, M. (2007) The folate receptor: What does it promise in tissue-targeted therapeutics?  Cancer Met. Rev. 26:141-152.

    Elnakat, H. and Ratnam, M. (2006) Role of folate receptor genes in reproduction and related cancers.  Frontiers in Bioscience 11:506-519.

    Qi, H. and Ratnam, M. (2006) Synergistic induction of folate receptor ß by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective antifolate cytotoxicty.  Cancer Res. 66:5875-5882.

    Tran, T., Shatnawi, A., Zheng, X., Kelley, K.K.M., and Ratnam, M. (2005) Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: A promising means to improved tumor detection and targeting.  Cancer Res. 65:4431-4441.

    Elnakat, H. and Ratnam. M. (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Delivery Rev. 56:1067-1084.

    Hao, H., Qi, H. and Ratnam, M. (2003) Modulation of folate receptor type ß gene by coordinate interactions of retinoic acid receptors at activator Sp1 and repressor AP1 sites. Blood 101:4551-4560.

    Kelley, K.M., Rowan, B.G. and Ratnam, M. (2003) Modulation of the folate receptor a gene by the estrogen receptor: Mechanism and implications in tumor targeting. Cancer Res. 63:2820-2828.

    Kelley, K.M., Wang, H. and Ratnam, M. (2003) Dual regulation of ets-activated gene expression by Sp1. Gene 27:87-97.

    Ratnam, M., Hao, H., Zheng, X., Wang, H., Qi, H., Lee, R. and Pan, X. (2003) Receptor induction and targeted drug delivery: a new antileukemia strategy. Expert Opin. Biol. Ther. 3: 563-574.

    Zheng, X., Yan, W., Kelley, K., Dorn, T. and Ratnam, M. (2003) Messenger RNA instability in the nucleus due to a novel ORF element is a major determinant of the narrow tissue specificity of folate receptor a. Mol. Cell. Biol. 23:2202-2212.

    Pan, X.Q., Zheng, X., Shi, G., Wang, H., Ratnam, M. and Lee, R.J. (Equal Contribution from the Ratnam and Lee Labs) (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor ß-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602.

    Wang, H., Zheng, X., Behm, F.-G. and Ratnam, M. (2000) Differentiation-independent retinoid induction of folate receptor b, a potential tumor target in myeloid leukemia. Blood 96:3529-3536.



    Page updated: November 20, 2009
    Page top
    • Prospective Students
    • Admission
    • Academics
    • Campus Life
    • Current Students
    • Faculty & Staff
    • Research
    • Athletics
    • Alumni & Community
    The University of Toledo • 2801 W. Bancroft • Toledo, OH 43606-3390 • 1.800.586.5336
    © 2006-2008 The University of Toledo. All rights reserved. • Send all feedback / comments to webmaster.
    • Terms of Use